AN2 Therapeutics
Innovative small molecule therapeutics targeting infectious diseases and oncology using boron chemistry.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $70.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
AN2 Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of novel small molecule therapeutics derived from its proprietary boron chemistry platform. The company is focused on addressing unmet medical needs in infectious diseases and oncology. AN2 Therapeutics is currently advancing a pipeline that includes epetraborole, an investigational drug aimed at treating Mycobacterium avium complex (MAC), the most common type of nontuberculous mycobacteria (NTM) lung disease. The company also has compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs targeting other infectious diseases and cancer. AN2 Therapeutics operates in the biopharmaceutical market, serving patients with serious and life-threatening conditions. Its business model involves obtaining non-dilutive funding from public and private agencies and foundations to advance its global health initiatives. The company generates revenue through the development and potential commercialization of its drug candidates, pending successful clinical trials and regulatory approvals.
Keywords: biopharmaceutical, boron chemistry, small molecule therapeutics, infectious diseases, oncology, epetraborole, NTM, Chagas disease, clinical trials, non-dilutive funding.